Clinical Trial Update: Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating whether prednisone can reduce side effects of pegylated interferon beta-1a in multiple sclerosis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• PREDNISONE (Prednisone)
• pegylated interferon beta-1a (interferon beta-1a pegylated)

Snippet

Sponsor: Holy Name Medical Center, Inc. | Conditions: Multiple Sclerosis | Phase 4 | Status: UNKNOWN